Argus raises Amgen stock price target on pipeline strength By Investing.com
Argus raises Amgen stock price target on pipeline strength By Investing.com Investing.com India
Covered in this story
What has happened since
- Amgen is down 0.3% since this was published.
Price move measured from the close nearest publication to the latest quote.
Tracked from this story
Argus Research’s $515 target on $AMGN is on the record and being tracked to Nov 2027 (12-month default), scored on the close that day.
Argus Research’s track record →Analyst targets on Amgen
- Freedom Broker: at $460 · target $470 by Nov 2027 · Hold via Investing.com
- Oppenheimer: at $439 · target $480 by Oct 2027 · Outperform via Investing.com India
- Scotiabank: at $432 · target $500 by Oct 2027 · outperform via MarketBeat
“At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $AMGN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Amgen →Dalsna Finance is currently tracking 49 stories mentioning Amgen, the earliest published 30 Mar 2026.
Summary aggregated from Investing.com India's public RSS feed. The full reporting belongs to Investing.com India — please read it on their site.